Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2006

View Archived Issues

URB-597 demonstrates anxiolytic and antidepressant effects in preclinical models

NNZ-3006 shows fat reduction capabilities in animal model

Juvista administration at time of surgery improves scar appearance

Ranbaxy presents novel linezolid analogues at ICAAC

R&D highlights from the UBS Global Life Sciences Conference in New York: Human Genome Sciences

Positive phase II results for Alpharma's abuse-deterrent, extended-release opioid

MediGene completes acquisition of Avidex

Inhibiting cathepsin K: effective blockade of bone resorption. Part I: clinical activity

PhotoCure completes phase IIa acne study of MAL cream

Studies examine effects of FTY-720 in multiple sclerosis

Imidacrine improves demyelinating disease in guinea pigs

Phase I studies determine CDP-323 pharmacokinetics, pharmacodynamics

Long-term ibandronate findings in postmenopausal osteoporosis presented

FDA requests additional trial to support approval of ruboxistaurin mesylate

Amgen to acquire Avidia

Innovive discontinues development of INNO-105

Gilead Sciences to acquire Myogen

Psychotropic compound Lu-AA44608 begins clinical testing

Avantogen files IND for phase II studies of RP-101 in metastatic pancreatic cancer

Nonclinical section of Onconase rolling NDA completed

EpiCept files IND for microtubulin inhibitor EPC-2407

Xenon and Takeda sign agreement for pain product XEN-401 in Japan and Asia

FM-VP4 completes phase II study in hypercholesterolemia

Alista has potential in female sexual arousal disorder

AS-1411 shows promise in renal and lung cancers

Novel BACE inhibitors emerge from Bristol-Myers Squibb R&D

Fast track designation for pralatrexate in T-cell lymphoma

Abbott begins roll-out of Xience V stent

Boehringer Ingelheim patent claims novel coagulation factor Xa inhibitors

Novel analgesic agents imparted in recent Pfizer patents

Cethromycin: preclinical and clinical update presented at the ICAAC meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...